Digitalis therapy in patients with ventricular tachyarrhythmias
Key result
Digitalis therapy shows no association with 3-year mortality following ventricular tachyarrhythmias.
- HR 1.063
- 95% CI 0.746-1.515
- P=0.736
- n=831
Why the study?
Data regarding the outcome of digitalis therapy following ventricular tachyarrhythmias is limited.
Does digitalis therapy reduce all-cause mortality in patients with ventricular tachyarrhythmias and atrial fibrillation and/or heart failure?
Comparison
Digitalis therapy vs no digitalis therapy
Design
Large retrospective registry cohort study
Follow-up
3 years
Authors
Discussion
Loading...
Member takes
Implication
Digitalis was associated with higher arrhythmic risk and rehospitalization but not mortality in VT/VF patients; hypothesis-generating and should not yet change practice.
Study Design
Type
Cohort (n=831)
Structured PICO
Does digitalis therapy reduce all-cause mortality in patients with ventricular tachyarrhythmias and atrial fibrillation and/or heart failure?
P
Population
831 consecutive patients with episodes of ventricular tachycardia or fibrillation, followed for 3 years.
E
Exposure
Digitalis therapy (digoxin or digitoxin)
C
Comparator
No digitalis therapy
O
Outcome
All-cause mortality at 3 yearshard clinical
Main Result
Hazard Ratio: 1.063 (95% CI 0.746–1.515)
Absolute Event Rate: 24% vs 21%
p-value: p=0.736
In patients with ventricular tachyarrhythmias, digitalis therapy does not improve survival and is associated with a higher risk of recurrent arrhythmias and cardiac rehospitalization.
Cite This Study
Schupp et al. (2022) conducted a cohort in Ventricular tachyarrhythmias (n=831). Digitalis therapy vs. No digitalis therapy was evaluated on All-cause mortality at 3 years (HR 1.063, 95% CI 0.746-1.515, p=0.736). Digitalis therapy was not associated with all-cause mortality at 3 years following ventricular tachyarrhythmias (24% vs 21%; HR 1.063; 95% CI 0.746-1.515; p=0.736).